| Stage | ABT | % of rev | CBT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $13.0B | 100.00% | $982M | 100.00% | ABT ×13.25 |
| Gross profit | $7.4B | 56.75% | $184M | 18.74% | ABT +38.0pp |
| Operating income | $1.4B | 10.44% | $98M | 9.98% | ABT +0.5pp |
| Pre-tax income | $1.2B | 9.46% | $58M | 5.91% | ABT +3.6pp |
| Net income | $920M | 7.07% | $14M | 1.43% | ABT +5.6pp |
| Stage | ABT | CBT | Gap · A − B |
|---|---|---|---|
| Revenue | $13.0B100.00% | $982M100.00% | ABT ×13.25 |
| Gross profit | 56.75%$7.4B | 18.74%$184M | ABT +38.0pp |
| Operating income | 10.44%$1.4B | 9.98%$98M | ABT +0.5pp |
| Pre-tax income | 9.46%$1.2B | 5.91%$58M | ABT +3.6pp |
| Net income |
| 7.07%$920M |
| 1.43%$14M |
| ABT +5.6pp |
No disclosed counterparties: CBT.
None